Description

Dose-response relationships and treatment durations for ALC in cognitive disorder trials are compared, showing that extended treatment periods tend to be associated with greater cognitive benefits.

Figure 3

Chart

Source Paper

Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update.

Nutrients (2020)

PMID: 32408706

DOI: 10.3390/nu12051389

Cite This Figure

![Figure 3: Dose-response relationships and treatment durations for ALC in cognitive disorder trials are compared, showing that extended treatment periods tend to be associated with greater cognitive benefits.]()

> Source: Manuela Pennisi et al. "Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update.." *Nutrients*, 2020. PMID: [32408706](https://pubmed.ncbi.nlm.nih.gov/32408706/)

<figure>
  <img src="" alt="Dose-response relationships and treatment durations for ALC in cognitive disorder trials are compared, showing that extended treatment periods tend to be associated with greater cognitive benefits." />
  <figcaption>Figure 3. Dose-response relationships and treatment durations for ALC in cognitive disorder trials are compared, showing that extended treatment periods tend to be associated with greater cognitive benefits.<br>  Source: Manuela Pennisi et al. "Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update.." <em>Nutrients</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32408706/">32408706</a></figcaption>
</figure>

Related Evidence

Omega-3 Fatty Acids (DHA/EPA) for Age-Related Cognitive Decline

Grade A · 58 studies

Omega-3 Fatty Acids (DHA/EPA) for Mild Cognitive Impairment (MCI)

Grade B · 18 studies

Acetyl-L-Carnitine for Age-Related Cognitive Decline

Grade C · 14 studies